We have located links that may give you full text access.
[18β-glycyrrhetinic acid piperazine derivative A30 inhibits the proliferation of SMMC-7721 hepatoma cells].
Xi Bao Yu Fen Zi Mian Yi Xue za Zhi = Chinese Journal of Cellular and Molecular Immunology 2017 September
Objective To investigate the mechanism of 18β-glycyrrhetinic acid (GA) piperazine derivative A30 on the antiproliferation of hepatocellular carcinoma SMMC-7721 cells in vitro. Methods The experiment included three groups: control group, 18β-GA group and A30 group. The proliferation activity was detected by MTT assay. Cell apoptosis and the change in the cycle of SMMC-7721 cells were evaluated by flow cytometry. Western blotting was used to observe the expressions of Bcl2 and caspase-8. Results The proliferation of SMMC-7721 cells was inhibited by A30 at the concentration of 2-128 μg/mL in a dose-dependent manner. 18β-GA and A30 could induce the apoptosis of SMMC-7721 cells, and the apoptosis rate of A30 group was significantly higher than that of the 18β-GA group. In the cell cycle analysis, the G2/M phase cells of 18β-GA and A30 groups increased remarkably as compared with the control group. A30 and 18β-GA could significantly enhance the expression of caspase-8, and decreased the expression of Bcl2. Conclusion The 18β-GA piperazine derivative A30 can inhibit the proliferation of SMMC-7721 cells in vitro, and the inhibitory effect is stronger than that of 18β-GA. The mechanism may be related to the inhibition of intracellular Bcl2 protein expression and the enhancement of caspase-8 expression.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app